In vivo hTO-induced Tauopathy / AD model
SynAging has established robust cognitive decline in hTO-treated mice within two weeks:
Three groups of mice, with 12 mice per group, were injected on day 0 bilaterally into the CA1 region of the hippocampus with:
- vehicle (Ctrl),
- 2 µg human tau oligomers (hTO),
- hTO + humanin (hTO + HNG)
The novel object recognition (NOR) assay was performed on day +15 and the spatial recognition assay (SRT) was performed at day +16. Mouse performance is shown as the discrimination index (DI), which is the difference of the active exploration time of the novel object / chamber, subtracted by that of the familiar object / chamber, divided by the total active exploration time.
Results clearly show a reproducible, strong and statistically significant change after injection with hTO, which can be prevented by co-injection with humanin. Further readouts (Y-maze, Morris water maze) are currently evaluated.
First results have been published as a poster at the Society for Neuroscience meeting in 2016, and another poster at the ADPD Meeting in Vienna 2017. Meanwhile, more than three independent reproductions of results have been obtained and the new hTO-induced mouse model is used for service at SynAging.